Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724446 | 0.99 | ALDH1A1 (0.32) | L3MBTL1ALDH1A1KMT2AAOC2HSD11B1 | |
| SCHEMBL3388570 | 0.82 | RORC (0.34) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL3387309 | 0.81 | RORC (0.33) | KMT2A | |
| SCHEMBL1710688 | 0.77 | AGTR2 (0.37) | ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL1710903 | 0.76 | HSD11B1 (0.34) | L3MBTL1ALDH1A1HSD11B1PNMT | |
| SCHEMBL1710530 | 0.76 | AGTR2 (0.37) | ALDH1A1KMT2A | |
| SCHEMBL3385727 | 0.75 | HSD11B1 (0.38) | L3MBTL1ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL3385709 | 0.74 | PSEN1 (0.37) | — | |
| SCHEMBL1723001 | 0.74 | HTR6 (0.43) | HSD11B1 | |
| SCHEMBL1725084 | 0.74 | GAA (0.38) | ALDH1A1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102203058-B | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2014-11-12 | — | — | CN | disclosed |
| CN-102203058-A | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2011-09-28 | — | — | CN | disclosed |
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | L3MBTL1 1514/4885ALDH1A1 314/4885KMT2A 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.